
CTI BioPharma Corp. CTIC
Quarterly report 2023-Q1
added 05-15-2023
CTI BioPharma Corp. Accounts Payables 2011-2026 | CTIC
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables CTI BioPharma Corp.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.01 M | 3.89 M | 1.64 M | - | 4.5 M | 2.59 M | 7.23 M | 10.6 M | 6.36 M | 5.05 M | 12.1 M | 5.75 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 12.1 M | 1.64 M | 5.6 M |
Quarterly Accounts Payables CTI BioPharma Corp.
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.02 M | 2.01 M | 2.44 M | 3.1 M | 2.42 M | 3.89 M | 1.78 M | 1.3 M | 1.17 M | 1.64 M | 1.64 M | 1.64 M | 1.64 M | - | - | - | - | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 2.59 M | 2.59 M | 2.59 M | 2.59 M | 7.23 M | 7.23 M | 7.23 M | 7.23 M | 10.6 M | 10.6 M | 10.6 M | 10.6 M | 6.36 M | 6.36 M | 6.36 M | 6.36 M | 5.05 M | 5.05 M | 5.05 M | 5.05 M | 12.1 M | 12.1 M | 12.1 M | 12.1 M | 5.75 M | 5.75 M | 5.75 M | 5.75 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 12.1 M | 1.17 M | 5.4 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AgeX Therapeutics
AGE
|
1.41 M | - | -10.17 % | $ 12.2 K | ||
|
Autolus Therapeutics plc
AUTL
|
1.97 M | $ 1.37 | -8.67 % | $ 350 M | ||
|
Aeglea BioTherapeutics
AGLE
|
677 K | - | - | $ 1.01 B | ||
|
Adagene
ADAG
|
4.24 M | $ 1.65 | 6.11 % | $ 92.9 M | ||
|
Biogen
BIIB
|
424 M | $ 177.93 | -4.15 % | $ 25.9 B | ||
|
Arrowhead Pharmaceuticals
ARWR
|
17.7 M | $ 65.89 | -0.06 % | $ 8.81 B | ||
|
Akero Therapeutics
AKRO
|
9.03 M | - | - | $ 3.67 B | ||
|
AVROBIO
AVRO
|
27 K | - | 1083.1 % | $ 745 M | ||
|
BeiGene, Ltd.
BGNE
|
405 M | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
486 K | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
10.1 M | - | -7.31 % | $ 87 M | ||
|
Codiak BioSciences
CDAK
|
1.84 M | - | -55.98 % | $ 2.15 M | ||
|
ARCA biopharma
ABIO
|
3.46 M | - | 1052.0 % | $ 415 M | ||
|
Bristol-Myers Squibb Company
BMY
|
3.6 B | $ 55.84 | 0.13 % | $ 113 B | ||
|
Cerevel Therapeutics Holdings
CERE
|
11.9 M | - | - | $ 7.29 B | ||
|
Acasti Pharma
ACST
|
601 K | - | 4.01 % | $ 150 M | ||
|
Caladrius Biosciences
CLBS
|
1.28 M | - | -16.75 % | $ 25.8 M | ||
|
Clearside Biomedical
CLSD
|
2.2 M | - | - | $ 25.3 M | ||
|
Chimerix
CMRX
|
2.85 M | - | - | $ 756 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
8.13 M | - | -15.15 % | $ 60.3 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
561 K | $ 4.18 | -1.65 % | $ 9.1 B | ||
|
Catalyst Biosciences
CBIO
|
355 K | $ 11.09 | 1.0 % | $ 730 M | ||
|
Albireo Pharma
ALBO
|
6.52 M | - | -0.23 % | $ 916 M | ||
|
Acer Therapeutics
ACER
|
3.81 M | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
4.29 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
247 K | - | 4.14 % | $ 49.1 M | ||
|
Ayala Pharmaceuticals
AYLA
|
4.08 M | - | - | $ 7.46 M | ||
|
Coherus BioSciences
CHRS
|
35.2 M | $ 1.69 | 2.12 % | $ 159 M | ||
|
Ampio Pharmaceuticals
AMPE
|
750 K | - | -11.43 % | $ 502 K | ||
|
Amphastar Pharmaceuticals
AMPH
|
30.5 M | $ 28.99 | -1.39 % | $ 1.4 B | ||
|
Celldex Therapeutics
CLDX
|
3.26 M | $ 25.71 | 0.16 % | $ 1.66 M | ||
|
Acorda Therapeutics
ACOR
|
13.4 M | - | -24.86 % | $ 820 K | ||
|
Applied Molecular Transport
AMTI
|
1.58 M | - | - | $ 10.1 M | ||
|
Brickell Biotech
BBI
|
406 K | - | -5.38 % | $ 6.06 M |